.tb-container[data-toolset-blocks-container="8c13577c35fd68d7b70a2a5270dfdf0d"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-container[data-toolset-blocks-container="93f4094e2a5fc591c3cbd3f80a56f302"] { border-radius: 10px;padding: 25px;box-shadow: 5px 5px 10px 1px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] { text-align: center; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px -5px rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__content { text-shadow: 5px 5px 10px rgba( 0, 0, 0, 0.5 );color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon { font-family: dashicons;margin-right: 10px; } .tb-button[data-toolset-blocks-button="905492d670a3f94a0bd953a7b3a4cad7"] .tb-button__icon::before { content: '\f103'; } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-fields-and-text[data-toolset-blocks-fields-and-text="d8ee833869d806ba93519c93a0c99d68"] { border-top: 1px dotted rgba( 0, 0, 0, 1 );border-right: 0px dashed rgba( 0, 0, 0, 1 );border-bottom: 0px dashed rgba( 0, 0, 0, 1 );border-left: 0px dashed rgba( 0, 0, 0, 1 ); } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] { text-align: center; } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="24f0f0d165901ec9701a2e67ad2f63d4"] .tb-button__icon { font-family: dashicons; } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] { text-align: center; } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link { background-color: rgba( 151, 91, 229, 1 );color: rgba( 255, 255, 255, 1 );box-shadow: 5px 5px 10px 0 rgba( 0, 0, 0, 0.5 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__link:visited { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__content { color: rgba( 255, 255, 255, 1 ); } .tb-button[data-toolset-blocks-button="f987862329ab3042d8c291515c549fdd"] .tb-button__icon { font-family: dashicons; } @media only screen and (max-width: 781px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 0.3333fr) minmax(0, 0.3333fr) minmax(0, 0.3333fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 2) { grid-column: 2 } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] > .tb-grid-column:nth-of-type(3n + 3) { grid-column: 3 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 0.5fr) minmax(0, 0.5fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 1) { grid-column: 1 } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] > .tb-grid-column:nth-of-type(2n + 2) { grid-column: 2 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } @media only screen and (max-width: 599px) { .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="ef19397a81dd17f19e5fc8b2cbc64a03"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="3034fbe886c11054e95b46b09d3e4112"] { display: flex; } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"] { grid-template-columns: minmax(0, 1fr);grid-auto-flow: row } .tb-grid[data-toolset-blocks-grid="3d9c399fe625e1b972f817a0680229f6"]  > .tb-grid-column:nth-of-type(1n+1) { grid-column: 1 } .tb-grid-column[data-toolset-blocks-grid-column="e863d66eac949908a5c6c8d2fd31320c"] { display: flex; }  } 
Báo cáo thường niên năm 2019 của Ionis Pharmaceuticals Inc.
Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development.
Báo cáo thường niên của Aurinia Pharmaceuticals Inc. năm 2019